Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005659700
Wed, 22.11.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin/Würzburg, 22 November 2023. Pentixapharm AG, a developer of innovative radiopharmaceuticals owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) today has announced that a first patient has been treated in a dose-finding clinical phase I/II study with Yttrium (90Y) anditixafortide (PentixaTher) at the University [ … ]
Tue, 21.11.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, November 21, 2023. Dr. Hakim Bouterfa, Executive Board member of Eckert & Ziegler AG and responsible for clinical development, will leave the Executive Board of Eckert & Ziegler AG at the end of the year and in future will concentrate exclusively on his tasks as Executive Board member of the Eckert & Ziegler subsidiary Pentixaph [ … ]
Tue, 14.11.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 14 November 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX) achieved sales of € 183.9 million in the first nine months of 2023 (previous year: € 165.8 million) and consolidated net income of € 20.3 million (previous year: € 21.7 million). Adjusted for currency losses of € 3.3 million, the nine-month resu [ … ]
Mon, 23.10.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany and Shanghai, China – 23 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Ablaze Pharmaceuticals (Ablaze) signed a comprehensive supply agreement for non-carrier added Lutetium-177 (n.c.a. 177Lu). Eckert & Ziegler will serve as the supplier for Ablaze’s clinical trial and research activities utilizing Lutetium-1 [ … ]
Fri, 20.10.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 20 October 2023. Berlin, xx.10.2023. The Executive Board of Eckert & Ziegler AG (ISIN DE0005659700, SDAX) resolved at its meeting today, with the approval of the Supervisory Board, the strategy and investment priorities for the coming years. In this context the Supervisory Board of Eckert & Ziegler AG has given its approval to the [ … ]
Tue, 10.10.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, Germany and BOCA RATON, FL, USA – 10 October 2023 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and PharmaLogic Holdings Corp. (“PharmaLogic”) have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225 (Ac-225). Under the terms of the agreement, PharmaLogic will have access to Eckert & Ziegler's h [ … ]
Thu, 28.09.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, September 28, 2023. Eckert & Ziegler AG has been awarded the Pankow 2023 Training Prize for outstanding training quality. The award was presented yesterday at a celebration event by Berlin-Pankow District Mayor Dr. Cordelia Koch.
The jury justified the award with the great commitment to professional training and the special training co [ … ]
Wed, 13.09.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Collaboration will develop and market Satellite Hot Labs for radiolabeling of BioGuides
Berlin, Germany – 13 September 2023 – Eckert & Ziegler (ISIN DE0005659700, TecDAX) today announced they have entered into a comprehensive collaboration agreement with RefleXion Medical, Inc. (RefleXion) and Telix Pharmaceuticals Limited (ASX:TLX, Telix) to [ … ]
Thu, 10.08.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Berlin, 10 August 2023. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, TecDAX) increased its sales by 10% to € 118.0 million in the first half of 2023. At € 10.9 million or € 0.52 per share, net income was € 3.5 million or 25% lower than in the same period last year. Currency effects in particular reduced the result by aro [ … ]
Thu, 08.06.2023
Eckert & Ziegler Strahlen- und Medizintechnik AG
Würzburg, Bavaria, 8 June 2023. PentixaPharm GmbH, a developer of innovative radiopharmaceuticals fully owned by Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700; TecDax) has received the approval from the German Federal Institute for Drugs and Medical Devices (BfArM) to start PTT101, its open-label dose escalation study to e [ … ]